NCT01489033已完成1 期
Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Phleum Pratense.
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Number and seriousness of both local and systemic adverse reactions
研究概览
简要总结
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic disease the aim of this study was to assess safety and tolerability of three different subcutaneous immunotherapy dose escalations in patients allergic to the pollen of Phleum pratense.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must sign the informed consent form.
- •Patients must be between 18 and 60 years of age.
- •Patients who obtained a prick test result greater or equal to 3 mm diameter and a specific IgE greater or equal to class 2 (CAP/PHADIA) to Phleum pratense.
- •Patients with seasonal allergic rhinoconjunctivitis against Phleum pratense during a minimum of 2 years prior to study participation. Although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild or moderate concomitant asthma is allowed.
- •Patients will preferably be monosensitized to Phleum pratense. Polysensitized patients to other seasonal allergens will be accepted if sensitizations are caused by Pollens whose seasons do not overlap with Phleum pratense.
- •Polysensitized patients to perennial allergens will also be accepted if not clinically relevant during the study period.
- •Women of childbearing potential must have a negative urine pregnancy test at Screening visit/Visit 0
- •Women of childbearing potential must agree to use an appropriate contraception method during the study if they are sexually active.
排除标准
- •Stable and continued use of medication for allergic pathology during 2 weeks prior to inclusion.
- •Patients sensitised to other overlapping seasonal allergens and with specific IgE levels greater or equal to class 2 CAP/PHADIA.
- •Patients who received immunotherapy in the previous 5 years for Phleum pratense or for any allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen.
- •Patients with severe asthma or FEV1 lower than 60% or asthma requiring inhaled or systemic corticoid treatment at the time of study entry or within 8 weeks prior to treatment commencement.
- •Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study.
- •Patients with a previous history of anaphylaxis
- •Patients with unstable angina
- •Patients with uncontrolled hypertension
- •Patients with clinically significant arrythmias
- •Patients with neoplasia
- •Patients with clinically relevant malformations of the upper respiratory tract.
- •Other chronic or immunological disease that could interfere with the assessment of the investigation product or that could generate any additional risk for the patient
- •Patients who have participated in another clinical trial within 3 month prior to enrolment.
- •Patients under treatment with tricyclic antidepressives, psychotropics or beta-blockers
- •Female patients who are pregnant or breast-feeding or women of childbearing potential that do not agree to use an appropriate contraception method during the study if they are sexually active, if they have not been surgical sterilised or present any other incapacity to bear
- •Patient who does not attend the visits
- •Patient's lack of collaboration or refusal to participate.
研究组 & 干预措施
Group A active
Experimental
6 administrations and 5 weeks duration
- Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals
- Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals.
干预措施: Subcutaneous immunotherapy with Phleum pratense pollen extract (Biological)
Group A placebo
Placebo Comparator
6 administrations and 5 weeks duration
- Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals
- Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals.
干预措施: Subcutaneous immunotherapy with Phleum pratense pollen extract (Biological)
Group B active
Experimental
8 administrations and 7 weeks duration
- Vial 1: 0.2 ml at 1 week intervals
- Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals
- Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals
干预措施: Subcutaneous immunotherapy with Phleum pratense pollen extract (Biological)
Group B placebo
Placebo Comparator
8 administrations and 7 weeks duration
- Vial 1: 0.2 ml at 1 week intervals
- Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals
- Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals
干预措施: Subcutaneous immunotherapy with Phleum pratense pollen extract (Biological)
Group C active
Experimental
8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
- Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval
- Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval
- Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval
- Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval
干预措施: Subcutaneous immunotherapy with Phleum pratense pollen extract (Biological)
Group C placebo
Placebo Comparator
8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
- Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval
- Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval
- Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval
- Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval
干预措施: Subcutaneous immunotherapy with Phleum pratense pollen extract (Biological)
结局指标
主要结局
Number and seriousness of both local and systemic adverse reactions
时间窗: From informed consent signature (V0) until the end of patient participation in the study (depending on the treatment assigned between 4 and 8 weeks )
次要结局
- Immunoglobulin levels (IgE specific, IgG total and IgG4) and prick test dose response(Before (V0) and after treatment (depending on the treatment assigned between 4 and 8 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)Allergic RhinoconjunctivitisNCT01489020Roxall Medicina España S.A48
已完成
2 期
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum PratenseAllergic RhinoconjunctivitisNCT01567306Roxall Medicina España S.A151
Unknown
不适用
Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLCNSCLC and TheropyNCT04530097Shanghai 10th People's Hospital260
终止
1 期
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisSclerosis, MultipleAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesNCT03540485Fundación Pública Andaluza para la gestión de la Investigación en Sevilla25
已完成
2 期
Dental Pain 3rd Molar Tooth Extraction GW842166PainNCT00444769GlaxoSmithKline112